Demographics and baseline characteristics of patients with newly diagnosed severe sarcoidosis-associated pulmonary hypertension

Male/female65 (52)/61 (48)
Age years57.5±10.6
BMI kg·m−225.5±6.6
Tobacco exposure42 (33)
Time between sarcoidosis and pulmonary hypertension diagnosis months204 (59–313)
Radiological stage
 I6 (5)
 II22 (17)
 III7 (6)
 IV91 (72)
WHO/NYHA functional class
 I–II21 (17)
 III79 (63)
 IV26 (20)
6MWD m319±143
Borg dyspnoea scale4.9±2.3
 RAP mmHg7±5
 mPAP mmHg46±10
 PAWP mmHg9±4
 Cardiac index L·min−1·m−22.6±0.8
 PVR Wood units8.8±4.3
SvO2 %63.4±8.9
Lung function tests
 FVC % pred64±21
 FEV1 % pred55±22
KCO % pred54±23
Long-term oxygen therapy68 (54)

Data are expressed as n, n (%), mean±sd or median (interquartile range). BMI: body mass index; WHO: World Health Organization; NYHA: New York Heart Association; 6MWD: 6-min walk distance; RAP: right atrial pressure; mPAP: mean pulmonary artery pressure; PAWP: pulmonary arterial wedge pressure; PVR: pulmonary vascular resistance; SvO2: mixed venous oxygen saturation; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; KCO: transfer coefficient of the lung for carbon monoxide.